View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 2, 2018

NanOlogy concludes dose escalation portion of NanoPac trial

NanOlogy has concluded the dose escalation portion of a Phase II, open-label clinical trial of NanoPac (submicron particle paclitaxel sterile suspension) for the treatment of prostate cancer.

NanOlogy has concluded the dose escalation portion of a Phase II, open-label clinical trial of NanoPac (submicron particle paclitaxel sterile suspension) for the treatment of prostate cancer.

The dose escalation phase was performed to determine highest concentration of NanoPac that can be safely administered.

In this phase, 6mg/ml, 10mg/ml, 15mg/ml concentrations of NanoPac were injected into three patient cohorts followed by a safety review for each cohort.

No drug related serious adverse events were observed in any of the cohorts and preliminary data show evidence of tumour reduction and tumour cell death.

"The drug injected locally has been well tolerated to date and we have progressed into the dose confirmation phase of the trial."

Completion of the dose escalation phase has also enabled NanOlogy to identify the highest concentration of NanoPac to begin the dose confirmation phase of the trial, which will continue to provide data on safety and tumour response.

NanOlogy has already started the dose confirmation phase, which will enrol nine additional patients for a total of 18 patients who received direct injection of NanoPac 28 days prior to their scheduled prostatectomy.

This phase will investigate the safety and tolerability as well as tumour size and histologic evidence of tumour response. It will also analyse the local lymph nodes to investigate potential lymphatic transport of NanoPac.

NanOlogy expects to complete and provide the final report of the trial by the third quarter of this year.

University of Southern California Institute of Urology Image-Guided Surgery and Focal Therapy of Prostate and Kidney Cancerco-director Andre Abreu said: “NanoPac is injected directly into the cancerous lobe of the prostate under MRI/TRUS fusion guidance.

“The drug injected locally has been well tolerated to date and we have progressed into the dose confirmation phase of the trial to further assess safety and tumour response.

“If we are successful, we may offer a treatment option for moderate or high-risk patients with localized or non-metastatic disease potentially providing better oncologic outcomes while minimising side-effects of chemotherapy, and therefore maintaining quality of life.”

Prostate cancer is estimated to affect around three million men in the US, with about 160,000 new cases and 27,000 deaths reported annually.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU